# A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

> **NCT01590641** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 49 (actual)

## Conditions studied

- Hepatitis B
- HBV

## Interventions

- **DRUG:** Single Ascending Dose (SAD) Cohorts GS-9620
- **DRUG:** Multiple Ascending Dose (MAD) Cohorts

## Key facts

- **NCT ID:** NCT01590641
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-09
- **Final completion:** 2013-10
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2013-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590641, "A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01590641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*